{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088335","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.772385+00:00","generated_at":"2026-06-12T03:58:03.888718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocular Therapeutix Q2 2023 DEXTENZA revenue $15M (+24% YoY), net loss $20.7M, $82.5M credit facility closed","bullets":["DEXTENZA net product revenue $15.0M in Q2 2023, up 24% from $12.1M in Q2 2022 and 14% sequentially.","Total net revenue $15.2M, up 24% YoY; net loss $(20.7)M or $(0.26) per share vs. $(18.8)M loss in Q2 2022.","Closed $82.5M Barings credit facility; net cash proceeds ~$51.6M after repayment of MidCap debt; cash runway extended into 2025.","First pivotal trial for OTX-TKI in wet AMD expected to initiate in Q3 2023; HELIOS Phase 1 NPDR trial enrollment completed.","Full-year 2023 DEXTENZA revenue guidance expected to be upper end of $55M-$60M range; board added Dr. Adrienne Graves in July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088335","json":"https://secwatch.observer/filing/0001104659-23-088335.json","markdown":"https://secwatch.observer/filing/0001104659-23-088335.md","text":"https://secwatch.observer/filing/0001104659-23-088335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/0001104659-23-088335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/tm2322873d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:58:03.888718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25d077bcc468d99b83ac57151a6c1aa83b63b787","claim":"OCULAR THERAPEUTIX, INC reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 7, 2023, Ocular Therapeutix, Inc. announced its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/0001104659-23-088335-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}